For monitoring heart palpitations, smartphone app provides comparable performance to 14-day event monitor

Patients in the University at Buffalo study found the AliveCor app “significantly easier to use” than ambulatory monitors

Release Date: May 5, 2016 This content is archived.

Print
Anne Curtis.
“The app is easier for patients to use and much more acceptable to them. ”
Anne B. Curtis, MD, Charles and Mary Bauer Chair and Professor of Medicine
Jacobs School of Medicine and Biomedical Sciences

BUFFALO, N.Y. – A smartphone app that tracks palpitations in heart patients provides comparable performance to the 14-day event monitors that are the current standard of care, according to a University at Buffalo study presented today at the annual Heart Rhythm Society (HRS) meeting in San Francisco.

Throughout the two-week study, 32 patients who had had some symptoms of cardiac arrhythmias, were required to use both methods to record when they were having palpitations.

The UB researchers found that the AliveCor Heart Monitor smartphone app correctly recorded 91 percent of total arrhythmic events experienced by patients versus 87.5 percent recorded by the event monitors.

“We showed that we can do as well with the app as with the event monitors,” said Anne B. Curtis, MD, the Charles and Mary Bauer Chair and Professor of Medicine in the Jacobs School of Medicine and Biomedical Sciences, and senior author. “The app is easier for patients to use and much more acceptable to them.”

Patients were far more likely to be compliant with the smartphone app, the study found, with 94 percent of patients complying with the smartphone app versus just 58 percent with the event monitor.

Conducted by cardiologists in the Department of Medicine in the Jacobs School of Medicine and Biomedical Sciences, the research was presented in a featured poster session at the HRS meeting on May 4.  

“The point of the study was to determine whether any smartphone app could be good enough to replace what we normally use now, which is a 14-30 day event monitor,” said Curtis, who is also chief executive officer of UBMD Internal Medicine.

She described the drawbacks to the event monitors that cardiac patients have to wear for anywhere from two to four weeks.

“The event monitors require electrocardiographic electrodes to be attached to the patient’s skin, which can be irritating,” she said. “Then the patient has to wear the device that is attached to the electrodes, which is somewhat cumbersome, and most patients do not like to wear it in public. Hence, compliance is often poor.”

With the event monitor, a patient experiencing palpitations must press a button to note they are having symptoms and then indicate what type of symptom it is either on a paper log or by inputting the information onto the monitor.

With the smartphone app, the patient experiencing palpitations puts a finger from each hand onto the surface of an electrode attached to a smartphone case. The data can then be uploaded to the AliveCor server through a secure, HIPAA-compliant transmission.

Deepika Narasimha, MD, formerly a medical resident in the Department of Medicine and now in the Division of Cardiology at Loma Linda Medical University is first author. UB co-authors are Nader Hanna, MD, medical resident, and Hiroko Beck, MD, Michael Chaskes, MD and Robert Glover, MD, all assistant professors of medicine; Gregory Gudleski, PhD, director of statistics and data management lab, Department of Medicine and Susan Danzer of UBMD Internal Medicine. Robert Gatewood of Buffalo Cardiology and Pulmonary Associates is also a co-author.

Media Contact Information

Ellen Goldbaum
News Content Manager
Medicine
Tel: 716-645-4605
goldbaum@buffalo.edu